Terms: = Kidney tumors AND PSA AND Staging
13 results:
1. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.
Falagario UG; Abbadi A; Remmers S; Björnebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
JAMA Netw Open; 2023 Sep; 6(9):e2332900. PubMed ID: 37695584
[TBL] [Abstract] [Full Text] [Related]
2. Early biochemical outcomes following PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results.
Francolini G; Ganovelli M; Di Cataldo V; Detti B; Caini S; Loi M; Simontacchi G; Desideri I; Greto D; Valzano M; Serni S; Vaggelli L; Salvestrini V; Visani L; Becherini C; Olmetto E; Franzese C; Baldaccini D; Scorsetti M; Sollini M; Chiti A; Meattini I; Valicenti RK; Livi L
Clin Exp Metastasis; 2023 Apr; 40(2):197-201. PubMed ID: 37012498
[TBL] [Abstract] [Full Text] [Related]
3. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
[TBL] [Abstract] [Full Text] [Related]
4. Primitive small cell carcinoma of the prostate. Case report and revision of the literature.
Pepe P; Pepe L; Curdman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2020 Dec; 92(4):. PubMed ID: 33348972
[TBL] [Abstract] [Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract] [Full Text] [Related]
6. Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer.
Sevcenco S; Klingler HC; Eredics K; Friedl A; Schneeweiss J; Knoll P; Kunit T; Lusuardi L; Mirzaei S
Adv Ther; 2018 Jun; 35(6):779-784. PubMed ID: 29777523
[TBL] [Abstract] [Full Text] [Related]
7. Our experience in the management of prostate cancer in renal transplant recipients.
Narváez A; Suarez J; Riera L; Castells-Esteve M; Cocera R; Vigués F
Actas Urol Esp (Engl Ed); 2018 May; 42(4):249-255. PubMed ID: 29395386
[TBL] [Abstract] [Full Text] [Related]
8. Living Donor kidney Transplantation After Brachytherapy for Prostate Cancer: Case Report.
Harada S; Ushigome H; Masuda K; Matsuyama T; Nakamura T; Koshino K; Iida T; Nobori S; Yoshimura N
Transplant Proc; 2017 Jun; 49(5):1187-1188. PubMed ID: 28583553
[TBL] [Abstract] [Full Text] [Related]
9. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract] [Full Text] [Related]
10. [Urologic malignancies in renal transplant candidates and recipients].
Kleinclauss F; Thuret R; Murez T; Timsit MO
Prog Urol; 2016 Nov; 26(15):1094-1113. PubMed ID: 27665407
[TBL] [Abstract] [Full Text] [Related]
11. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract] [Full Text] [Related]
12. [Positron emission tomography (PET): application in urogenital system oncologic diseases].
Lomeña F; Simó M; Setoain X; Pérez G
Arch Esp Urol; 2001; 54(6):649-60. PubMed ID: 11512406
[TBL] [Abstract] [Full Text] [Related]
13. The staging of M+ disease.
Bouffioux C; Bollack C; Scher H
Prog Clin Biol Res; 1990; 357():185-91. PubMed ID: 2217462
[TBL] [Abstract] [Full Text] [Related]
